Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology (Genome Sequencing, PCR, Microarray, Nucleic Acid Extraction and Purification), By End-use (Hospitals, Research Institutes, Academic Institutes) And Segment Forecasts To 2022
Global genomics in cancer care market is expected to reach USD 9.22 billion by 2022, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.
In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.
Further key findings from the study suggest:
Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.
Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.
The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.
Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.
In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.
Further key findings from the study suggest:
Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.
Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.
Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.
Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.
The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.
Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research methodology
1.2. Research scope & assumptions
1.3. List of data sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Genomics in cancer care- Industry Snapshot And Key Buying Criteria, 2012-2022
CHAPTER 3. GENOMICS IN CANCER CARE INDUSTRY OUTLOOK
3.1. Genomics in cancer care market segmentation
3.2. Genomics in cancer care market size and growth prospects
3.3. Genomics in cancer care market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis - Porter's
3.6. Genomics in cancer care market PESTEL analysis, 2014
CHAPTER 4. GENOMICS IN CANCER CARE PRODUCT OUTLOOK
4.1. Genomics in cancer care market share by product, 2014 & 2022
4.2. Instruments
4.2.1. Instruments market, 2012-2020 (USD Million)
4.3. Consumables & reagents
4.3.1. Consumables & reagents market, 2012 - 2020 (USD Million)
4.4. Services
4.4.1. Services market estimates and forecasts, 2012 f 2022 (USD Million)
CHAPTER 5. GENOMICS IN CANCER CARE APPLICATION OUTLOOK
5.1. Genomics in cancer care revenue share by application, 2013 & 2020
5.2. Diagnostics
5.2.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
5.3. Personalized medicine
5.3.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
5.4. Drug discovery & development
5.4.1.Market estimates and forecasts, 2012 - 2020 (USD Million)
5.5. Research
5.5.1. Market estimates and forecasts, 2012 - 2020 (USD Million))
CHAPTER 6. GENOMICS IN CANCER CARE TECHNOLOGY OUTLOOK
6.1. Genomics in cancer care revenue share by technology, 2013& 2020
6.2. Genome sequencing
6.2.1. Genome sequencing market estimates and forecasts, 2012 - 2020 (USD Million)
6.3. Polymerase chain reaction (PCR)
6.3.1. PCR market estimates and forecasts, 2012 - 2020 (USD Million)
6.4. Microarray
6.4.1. Microarray market estimates and forecasts, 2012 - 2020 (USD Million)
6.5. Nucleic acid extraction and purification
6.5.1. Nucleic acid extraction and purification market estimates and forecasts, 2012 - 2020 (USD Million)
6.6. Other (Flow cytometry, Bioinformatics)
6.6.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)
CHAPTER 7. GENOMICS IN CANCER CARE END-USE OUTLOOK
7.1. Genomics in cancer care revenue share by end-use, 2013& 2020
7.2. Hospitals
7.2.1. Hospitals market estimates and forecasts, 2012 - 2020 (USD Million)
7.3. Research institutes
7.3.1. Research institutes market estimates and forecasts, 2012 - 2020 (USD Million)
7.4. Academic institutes
7.4.1. Academic institutes market estimates and forecasts, 2012 - 2020 (USD Million)
7.5. Others (diagnostic labs, commercial organizations & physician office)
7.5.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)
CHAPTER 8. GENOMICS IN CANCER CARE REGIONAL OUTLOOK
8.1. Genomics in cancer care market share by region, 2014 & 2022
8.2. North America
8.2.1. North America Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
8.2.1.1. U.S. Market Estimates and Forecasts
8.2.1.2. Canada Market Estimates and Forecasts
8.3. Europe
8.3.1. Europe Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
8.3.1.1. Germany Market Estimates and Forecasts
8.3.1.2. UK Market Estimates and Forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.4.1.1. Japan Market Estimates and Forecasts
8.4.1.2. China Market Estimates and Forecasts
8.4.1.3. India Market Estimates and Forecasts
8.5. Latin America
8.5.1. Latin America Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.5.1.1. Brazil Market Estimates and Forecasts
8.5.1.2. Mexico Market Estimates and Forecasts
8.6. MEA
8.6.1. MEA Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.6.1.1. South Africa Estimates and Forecasts
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Illumina Inc
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Roche Diagnostics
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Cancer Genetics Inc
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Bio-Rad Laboratories
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Sigma Aldrich
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Qiagen
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Perkin Elmer
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Affymetrix
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. BGI
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. Life technologies
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. GE Healthcare
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives
9.13. Pacific Biosciences
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Strategic Initiatives
9.14. Quest Diagnostics
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Strategic Initiatives
9.15. Myriad Genetics
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Strategic Initiatives
9.16. Luminex
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Strategic Initiatives
9.17. Abbott Molecular
9.17.1. Company Overview
9.17.2. Financial Performance
9.17.3. Product Benchmarking
9.17.4. Strategic Initiatives
9.18. Beckman Coulter, Inc
9.18.1. Company Overview
9.18.2. Financial Performance
9.18.3. Product Benchmarking
9.18.4. Strategic Initiatives
9.19. Oxford Gene Technology Ltd.
9.19.1. Company Overview
9.19.2. Financial Performance
9.19.3. Product Benchmarking
9.19.4. Strategic Initiatives
1.1. Research methodology
1.2. Research scope & assumptions
1.3. List of data sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Genomics in cancer care- Industry Snapshot And Key Buying Criteria, 2012-2022
CHAPTER 3. GENOMICS IN CANCER CARE INDUSTRY OUTLOOK
3.1. Genomics in cancer care market segmentation
3.2. Genomics in cancer care market size and growth prospects
3.3. Genomics in cancer care market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis - Porter's
3.6. Genomics in cancer care market PESTEL analysis, 2014
CHAPTER 4. GENOMICS IN CANCER CARE PRODUCT OUTLOOK
4.1. Genomics in cancer care market share by product, 2014 & 2022
4.2. Instruments
4.2.1. Instruments market, 2012-2020 (USD Million)
4.3. Consumables & reagents
4.3.1. Consumables & reagents market, 2012 - 2020 (USD Million)
4.4. Services
4.4.1. Services market estimates and forecasts, 2012 f 2022 (USD Million)
CHAPTER 5. GENOMICS IN CANCER CARE APPLICATION OUTLOOK
5.1. Genomics in cancer care revenue share by application, 2013 & 2020
5.2. Diagnostics
5.2.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
5.3. Personalized medicine
5.3.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
5.4. Drug discovery & development
5.4.1.Market estimates and forecasts, 2012 - 2020 (USD Million)
5.5. Research
5.5.1. Market estimates and forecasts, 2012 - 2020 (USD Million))
CHAPTER 6. GENOMICS IN CANCER CARE TECHNOLOGY OUTLOOK
6.1. Genomics in cancer care revenue share by technology, 2013& 2020
6.2. Genome sequencing
6.2.1. Genome sequencing market estimates and forecasts, 2012 - 2020 (USD Million)
6.3. Polymerase chain reaction (PCR)
6.3.1. PCR market estimates and forecasts, 2012 - 2020 (USD Million)
6.4. Microarray
6.4.1. Microarray market estimates and forecasts, 2012 - 2020 (USD Million)
6.5. Nucleic acid extraction and purification
6.5.1. Nucleic acid extraction and purification market estimates and forecasts, 2012 - 2020 (USD Million)
6.6. Other (Flow cytometry, Bioinformatics)
6.6.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)
CHAPTER 7. GENOMICS IN CANCER CARE END-USE OUTLOOK
7.1. Genomics in cancer care revenue share by end-use, 2013& 2020
7.2. Hospitals
7.2.1. Hospitals market estimates and forecasts, 2012 - 2020 (USD Million)
7.3. Research institutes
7.3.1. Research institutes market estimates and forecasts, 2012 - 2020 (USD Million)
7.4. Academic institutes
7.4.1. Academic institutes market estimates and forecasts, 2012 - 2020 (USD Million)
7.5. Others (diagnostic labs, commercial organizations & physician office)
7.5.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)
CHAPTER 8. GENOMICS IN CANCER CARE REGIONAL OUTLOOK
8.1. Genomics in cancer care market share by region, 2014 & 2022
8.2. North America
8.2.1. North America Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
8.2.1.1. U.S. Market Estimates and Forecasts
8.2.1.2. Canada Market Estimates and Forecasts
8.3. Europe
8.3.1. Europe Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
8.3.1.1. Germany Market Estimates and Forecasts
8.3.1.2. UK Market Estimates and Forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.4.1.1. Japan Market Estimates and Forecasts
8.4.1.2. China Market Estimates and Forecasts
8.4.1.3. India Market Estimates and Forecasts
8.5. Latin America
8.5.1. Latin America Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.5.1.1. Brazil Market Estimates and Forecasts
8.5.1.2. Mexico Market Estimates and Forecasts
8.6. MEA
8.6.1. MEA Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
8.6.1.1. South Africa Estimates and Forecasts
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Illumina Inc
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Agilent Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Roche Diagnostics
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Cancer Genetics Inc
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Bio-Rad Laboratories
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Sigma Aldrich
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Qiagen
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Perkin Elmer
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Affymetrix
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. BGI
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. Life technologies
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. GE Healthcare
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives
9.13. Pacific Biosciences
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Strategic Initiatives
9.14. Quest Diagnostics
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Strategic Initiatives
9.15. Myriad Genetics
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Strategic Initiatives
9.16. Luminex
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Strategic Initiatives
9.17. Abbott Molecular
9.17.1. Company Overview
9.17.2. Financial Performance
9.17.3. Product Benchmarking
9.17.4. Strategic Initiatives
9.18. Beckman Coulter, Inc
9.18.1. Company Overview
9.18.2. Financial Performance
9.18.3. Product Benchmarking
9.18.4. Strategic Initiatives
9.19. Oxford Gene Technology Ltd.
9.19.1. Company Overview
9.19.2. Financial Performance
9.19.3. Product Benchmarking
9.19.4. Strategic Initiatives
